Droice Labs takes part in
Pharmstars 2021 accelerator
Droice Labs successfully completed the 10 week long pharma-focussed Pharmstars accelerator program.
Pharmstars accelerator aims to bridge the gap between pharma and innovative startups that offer novel solutions to address challenges in the areas of digital health solutions, digital biomarkers, patient engagement, clinical trial recruitment, novel drug delivery mechanisms, real-world evidence (RWE) collection, and data analysis. The startups get to partner with top pharma companies including Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Sumitovant Biopharma, and others.
Droice Labs utilized this opportunity to present our data enablement and real-world evidence generation capabilities from electronic medical records and other unstructured data sources for pharma, and aims to work closely with pharma companies to implement the solution in the near future.
The article can be found here.